Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 11/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1498398 | 1.00 | RORC (0.50) | RORCCACNA1BCYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1498399 | 1.00 | RORC (0.50) | RORCCACNA1BCYP3A4CYP2C19CYP2D6 | |
| SCHEMBL12542545 | 0.91 | RORC (0.51) | RORCCACNA1BCYP3A4CYP2C19CYP2D6 | |
| SCHEMBL12542544 | 0.91 | RORC (0.51) | RORCCACNA1BCYP3A4CYP2C19CYP2D6 | |
| SCHEMBL12688390 | 0.86 | DRD2 (0.46) | RORC | |
| SCHEMBL12688463 | 0.86 | DRD2 (0.46) | RORC | |
| SCHEMBL10476062 | 0.86 | CCR2 (0.52) | CACNA1BCCR2 | |
| SCHEMBL10476055 | 0.86 | CCR2 (0.52) | CACNA1BCCR2 | |
| SCHEMBL10476054 | 0.86 | CCR2 (0.52) | CACNA1BCCR2 | |
| SCHEMBL12688439 | 0.84 | RORC (0.47) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1A | RORC 1695/4885CACNA1B 6/4885CYP3A4 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.